A Comprehensive Strategy to Discover Inhibitors of the Translesion Synthesis DNA Polymerase κ
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Human DNA polymerase kappa (pol κ) is a translesion synthesis (TLS) polymerase that catalyzes TLS past various minor groove lesions including N(2)-dG linked acrolein- and polycyclic aromatic hydrocarbon-derived adducts, as well as N(2)-dG DNA-DNA interstrand cross-links introduced by the chemotherapeutic agent mitomycin C. It also processes ultraviolet light-induced DNA lesions. Since pol κ TLS activity can reduce the cellular toxicity of chemotherapeutic agents and since gliomas overexpress pol κ, small molecule library screens targeting pol κ were conducted to initiate the first step in the development of new adjunct cancer therapeutics. A high-throughput, fluorescence-based DNA strand displacement assay was utilized to screen ∼16,000 bioactive compounds, and the 60 top hits were validated by primer extension assays using non-damaged DNAs. Candesartan cilexetil, manoalide, and MK-886 were selected as proof-of-principle compounds and further characterized for their specificity toward pol κ by primer extension assays using DNAs containing a site-specific acrolein-derived, ring-opened reduced form of γ-HOPdG. Furthermore, candesartan cilexetil could enhance ultraviolet light-induced cytotoxicity in xeroderma pigmentosum variant cells, suggesting its inhibitory effect against intracellular pol κ. In summary, this investigation represents the first high-throughput screening designed to identify inhibitors of pol κ, with the characterization of biochemical and biologically relevant endpoints as a consequence of pol κ inhibition. These approaches lay the foundation for the future discovery of compounds that can be applied to combination chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The development of drugs interfering with different aspects of the TLS pathway was also attempted with promising results [113,114,115,116]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [116]
In the citing paper
“These compounds, however, cannot achieve complete TLS inhibition.”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 42 · Cited by 35
Metadata
- Authors
- Yamanaka, K., Dorjsuren, D., Eoff, R. L., Egli, M., Maloney, D. J., Jadhav, A., Simeonov, A., & Lloyd, R. S.
- Affiliations
- Oregon Health & Science University (US)
- National Institutes of Health (US)
- University of Arkansas for Medical Sciences (US)
- Vanderbilt University (US)
- Corresponding author
- Lloyd, R. Stephen
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-08
- Volume
- 7
- Issue
- 10
- Pages
- e45032
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3466269
- OpenAlex
- W2139146509
- Cited by
- 35
- References
- 42
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 5 · 2015: 2 · 2014: 2 · 2013: 4
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Vanderbilt University
- University of California, San Francisco
- National Institute of Mental Health (R03MH094179, R03 MH)
- National Cancer Institute (R01CA106858, CA 106858, P01CA160032)
- National Institute of General Medical Sciences (GM084460, T32GM071338, R00GM084460)
- National Institute of Environmental Health Sciences (P01ES005355, ES 05355)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- DNA polymerase kappa, translesion synthesis, polymerase inhibitors, small molecule screening, candesartan cilexetil, manoalide, MK-886, polycyclic aromatic hydrocarbons, mitomycin C, UV-induced DNA damage, glioma, combination chemotherapy
- MeSH terms
- Y-Family DNA Polymerases, Acrolein, Benzimidazoles, Biphenyl Compounds, Cell Line, Transformed, Cell Survival, Chlorobenzenes, Deoxyguanosine, DNA, DNA Damage, DNA-Directed DNA Polymerase, DNA Repair, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Enzyme Inhibitors, Humans, Indoles, Terpenes, Tetrazoles, Ultraviolet Rays, DNA Adducts, Nucleic Acid Synthesis Inhibitors, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comprehensive Strategy to Discover Inhibitors of the Translesion Synthesis DNA Polymerase κ. https://app.cochat.ai/papers/10.1371/journal.pone.0045032
- The paper
- Yamanaka, K., Dorjsuren, D., Eoff, R. L., Egli, M., Maloney, D. J., Jadhav, A., Simeonov, A., & Lloyd, R. S. (2012). A Comprehensive Strategy to Discover Inhibitors of the Translesion Synthesis DNA Polymerase κ. PLoS ONE. https://doi.org/10.1371/journal.pone.0045032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.